Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive early breast cancer.
This is written in the approval document as:
HER2 positive early breast cancer (EBC).
Citation
Trastuzumab (IV) Monotherapy - 21 days, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab |